Kiwi Biosciences

fodzyme.com →

-85%

est. 2Y upside i

HealthcareSeed

Patent-pending enzymes to break down common dietary triggers

Rank

#418

Sector

Biotechnology

Est. Liquidity

~5Y

Data Quality

Data: Medium

This opportunity is highly speculative, offering moderate upside potential driven by innovative enzyme technology for IBS, but is overshadowed by critically low funding and a 'deadpooled' UK entity, indicating significant financial and operational risks for a job seeker's equity.

Last updated: February 16, 2026

Bull (25%)+500%

Strong market adoption of FODZYME and successful further funding rounds lead to a strategic acquisition at a high multiple, leveraging its patent-pending enzyme technology.

Base (30%)+125%

Continued modest growth and product refinement, but limited market penetration and funding challenges, resulting in a small acquisition or continued operation as a niche player.

Bear (45%)-90%

Intense competition, insufficient funding, or broader operational challenges signaled by the 'deadpooled' UK entity lead to a significant loss of value or company shutdown.

Est. time to liquidity~5.0 years

Community

Valuation Sentiment

Our model estimates -85% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.